Fintel reports that on December 3, 2025, BMO Capital maintained coverage of Amgen (NasdaqGS:AMGN) with a Outperform ...

Amgen’s stock narrative is shifting, as reflected in a slight but noticeable increase in the consensus analyst price target ...

Amgen Inc. stock has reached a new 52-week high, hitting $345.95, marking a significant milestone for the biotechnology company. The stock is now trading just 0.99% from its 52-week high of $345.84.

Curious if Amgen is worth your investment dollars right now? Let’s take a clear-eyed look at where the stock stands and ...

Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.

William Blair starts coverage of Viridian, citing veligrotug's advantages over Tepezza and key 2026 catalysts, including FDA ...

According to Benzinga Pro, Amgen Inc's peer group average for short interest as a percentage of float is 6.86%, which means ...

An analyst bumped his price target higher on the shares. He didn't change his recommendation, however. 10 stocks we like better than Amgen › On Tuesday, Amgen (NASDAQ: AMGN) stock hit its one-year ...

The pharmaceutical sector mainstay earned several positive mentions in the pundit sphere that day. In Jim Cramer's "Stop Trading" segment on CNBC's Squawk on the Street program, the famous stock ...

On Tuesday, Amgen (NASDAQ: AMGN) stock hit its one-year high, on continued momentum from a far better-than-expected quarterly earnings report. The immediate catalyst was a post-earnings price target ...

As of Wednesday, November 26, Arrowhead Pharmaceuticals, Inc.’s ARWR share price has surged by 9.30%, which has investors ...